L-Carnitin Fresenius

Levocarnitine, the active ingredient in L-Carnitin Fresenius, is a carnitine presented as an oral nutritional supplement for oral use. It supports energy metabolism by facilitating the transport of long‑chain fatty acids into mitochondria and is used in patients with carnitine deficiency or metabolic conditions requiring supplementation.

GNH USA supplies L-Carnitin Fresenius as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Levocarnitine is employed to address disorders related to impaired carnitine metabolism and to support energy production in specific clinical settings.

- Primary carnitine deficiency: restores normal plasma carnitine levels and improves muscle function. - Secondary carnitine deficiency (e.g., dialysis patients): reduces fatigue and supports metabolic stability. - Fatty acid oxidation disorders: assists in the oxidation of long‑chain fatty acids, mitigating hypoglycaemia. - Metabolic support in renal or hepatic impairment: helps maintain energy homeostasis during chronic disease.

Levocarnitine is generally well tolerated, but some patients may experience adverse reactions.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Vomiting: occasional episodes, especially with high initial doses. - Diarrhoea: loose stools that resolve with continued therapy. - Abdominal discomfort: cramping or bloating. - Fish‑like body odor: due to metabolic by‑products. - Headache: transient and usually mild.

Serious or Rare Side Effects: - Hypersensitivity reactions: rash, pruritus, or angioedema. - Anaphylaxis: rare but potentially life‑threatening. - Severe metabolic acidosis: especially in patients with renal failure. - Cardiac arrhythmias: reported in isolated cases. - Seizure exacerbation: in predisposed individuals. - Liver enzyme elevation: monitor in patients with hepatic disease.

When prescribing Levocarnitine, clinicians should consider the following precautions.

- Renal function assessment: adjust dose in patients with impaired clearance. - Plasma carnitine monitoring: ensure therapeutic levels and avoid excess. - Hypersensitivity screening: discontinue if allergic reactions occur. - Seizure disorders: use cautiously as it may lower seizure threshold. - Concomitant medications: review for potential interactions. - Store at ambient temperature: keep below 25°C, in the original packaging, protected from moisture and direct sunlight.

Levocarnitine may interact with certain drugs, requiring monitoring.

Major Interactions (Avoid): - Valproic acid: may reduce its plasma concentration and efficacy. - Carbamazepine: can lower levocarnitine levels, diminishing therapeutic effect.

Moderate Interactions (Monitor Closely): - Warfarin: may affect INR; monitor coagulation parameters. - Thyroid hormone replacement: may require dose adjustment of levocarnitine. - Other nutritional supplements: combined use can increase gastrointestinal discomfort. - Antibiotics (e.g., aminoglycosides): monitor renal function closely when co‑administered.